ArticleDermatology and therapy2026
Effectiveness and Safety of 40 mg Modified-Release Doxycycline for the Treatment of Hidradenitis Suppurativa: A Single-Center Retrospective Observational Study.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHidradenitis suppurativa (HS) is a chronic inflammatory follicular disorder commonly managed with antibiotics, despite increasing antimicrobial resistance (AMR).
methodsThis single-center retrospective study evaluated the efficacy and safety of 40 mg modified-release doxycycline (MR-DC) in 66 adults with HS treated for 28 days.
resultsResponse to treatment was assessed using the Hidradenitis Suppurativa Clinical Response (HiSCR) and the International Hidradenitis Suppurativa Severity Score System (IHS4) scales. Specifically, at 12 weeks, HiSCR50 and IHS4-55 responses were achieved in 75.8% and 87.9% of patients, respectively. Relapse occurred in 33% at 6 months. Lower baseline IHS4, shorter disease duration, lower BMI, higher total inflammatory nodule and abscess count, absence of involvement of the pubis and genital area, and use of concomitant treatment were associated with better outcomes; only shorter disease duration remained significant on multivariate analysis (P < 0.022). Compared to results from other studies using standard regimens of regular-release doxycycline (RR-DC), MR-DC appears to have similar efficacy and more favorable safety profile.
conclusionsLow-dose MR-DC may be an effective short-term treatment or adjunctive therapeutic option for HS flares, with a reduced risk of AMR and adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.